Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced, Refractory or Recurrent Ovarian Cancer

NCT00058552 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00058552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00058552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced, Refractory or Recurrent Ovarian Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2003
Completion date
July 31, 2004
Enrollment
129 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer